Business
Cognition Therapeutics Announces Participation in Upcoming September Conferences
PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that
About this update from Cognition Therapeutics, Inc.
[{"type":"text","content":"PURCHASE, N.Y., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways (the “Company” or “Cognition”), announced that Lisa Ricciardi, Chief Executive Officer, will deliver a company presentation at the H.C. Wainwright Annual Global Investment Conference and participating on a panel at the Cantor Fitzgerald Global Healthcare Conference in September 2023. In addition, she will be moderating a panel on pipeline prioritization strategies at the Longwood Healthcare Leaders Fall Conference, a brainstorming forum of pharmaceutical, healthcare and investment leaders focused on accelerating the translation of discoveries into medicines. Presentation Details: H.C. Wainwright Annual Global Investment Conference Dates: September 11-13, 2023Presentation Day/Time: September 13 at 4:00 pmLocation: Kennedy II, Lotte New York Palace, New YorkLive webcast will be available on the events and presentations section of Cognition’s IR site during the event Longwood Healthcare Leaders Fall Conference Dates: September 18-19, 2023Presentation Day/Time: September 19 at 4:10pmLocation: Harvard Medical School, Boston Cantor Fitzgerald Global Healthcare Conference Dates: September 26-28, 2023Presentation Day/Time: September 26 at 9:20 amLocation: Intercontinental Barclay Hotel, New YorkLive webcast will be available on the events and presentations section of Cognition’s IR site during the event About Cognition Therapeutics:Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics an...